July 17, 2014 | Alcobra Pharmaceuticals filed a prospectus for a $100 million offering on NASDAQ. The company has developed alternative drugs for the treatment of ADHD based on its research. In May 2013, Alcobra’s IPO raised $25 million at a company value of $89 million. As of today, Alcobra is worth $260 million. The filing for the offering comes as Alcobra announces patient recruitment for Phase III clinical trials for its treatment for ADHD.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Facebook comments